Gabe Jackson gets up with the grounds crew to convert Covenant Health Park for soccer
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Jim Cramer Says He 'Was Discouraged to Get a Mixed Update from Abbott Labs'
Abbott Laboratories (NYSE:ABT) is one of the stocks that Jim Cramer shed light on. Commenting on the company's recent earnings report results, Cramer said: 'Today, in an otherwise positive market, I was discouraged to get a mixed update from Abbott Labs, medical technology company that we've long owned for the Charitable Trust… I'd say two decades. When Abbott Labs reported this morning, the… results were perfectly solid. Management tightened their full-year earnings guidance rather than raising it while also taking down their organic sales growth forecast and their operating margin outlook. wavebreakmedia/ Abbott (NYSE:ABT) is a healthcare company engaged in the research, development, manufacture, and marketing of a wide range of medical products. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
18 minutes ago
- Yahoo
Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition
Eli Lilly and Company (NYSE:LLY) is one of the . Amid carrying on new studies, the company has agreed to acquire Verve Therapeutics. Eli Lilly and Company (NYSE:LLY) is a research-driven pharmaceutical leader headquartered in Indiana. With a 150-year history, the company carries on the business of discovering, developing, manufacturing, and marketing innovative treatments across diseases like diabetes and in fields like oncology, immunology, and neuroscience. Some of the company's notable products, such as Humalog, Trulicity, Mounjaro, and Zepbound, are marketed in over 125 countries. The company is carrying on multiple studies and its latest updates include the Phase 2b clinical study titled 'A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa' and Phase 3 clinical study titled 'A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Efficacy and Safety Study of Lebrikizumab/ LY3650150 in Adults With Chronic Rhinosinusitis With Nasal Polyps on a Background Therapy With Intranasal Corticosteroids.' Along with these studies, the company has a pipeline with potential drugs capable of generating more than $1 billion in annual revenue. Amid these studies, the company has agreed to buy Verve Therapeutics Inc. for up to $1.3 billion. With this acquisition, Eli Lilly and Company (NYSE:LLY) aims to strengthen its positions in gene editing for cardiovascular conditions. With a beta of 0.44 signaling the company's resistance to market conditions, Eli Lilly and Company (NYSE:LLY) has a high anticipated 5-year EPS growth of 41.87%, making the stock a strong contender in our list. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025 Disclosure. None.
Yahoo
18 minutes ago
- Yahoo
Bears $24 million playmaker could lose job during training camp
The 2025 Chicago Bears will be about how the offense handles new head coach Ben Johnson with second-year quarterback Caleb Williams. Last season, the Bears' offense had a lot of ups and downs, which is why the team went out and hired Johnson to ensure Williams can improve in Year 2. One way Williams can have a better season than last year is if he gets support from the running game, but the team failed to upgrade the position this offseason. The Bears only brought in Rutgers running back Kyle Monangai, who was drafted in the seventh round to go along with Roschon Johnson, D'Andre Swift, and Travis Homer. As of right now, Swift is No. 1 running back on the depth chart, but Bryan Perez from Bears On SI thinks Swift could lose his job if he doesn't have a strong training camp."This one's obvious. The Bears inked Swift to a three-year, $24 million contract last offseason, but that doesn't matter now. Maybe they wouldn't have if Johnson were the head coach. And now that Johnson is in town, he'll decide what Swift's future with the team is," Perez wrote. "That future could very well be a bell cow running back who vaults into the top-10 running backs in the NFL. Swift certainly has the explosive skill set to be that guy, but if 2024's production was an indication of the kind of player he'll be in Chicago, it won't be long before Roschon Johnson or rookie Kyle Monangai replaces him." In one season in Chicago, Swift rushed for 959 yards and six scores, but those numbers will have to improve if he wants to be the lead back all season in the Windy City.
